Key Takeaways
- Two major doctor groups now back hormone therapy.
- The ACP endorses it first-line for hot flashes.
- Timing matters: earlier is safer.
A First-Line Endorsement
The conversation around menopause hormone therapy has shifted again — this time with a first.
For the first time, the American College of Physicians (ACP) has endorsed hormone therapy as a first-line treatment for hot flashes and night sweats, the vasomotor symptoms that affect an estimated 80% of women during the menopause transition. The ACP guideline was published October 6, 2026, in Annals of Internal Medicine.
The ACP recommends estrogen alone for women who have had a hysterectomy, and estrogen combined with progesterone for women with a uterus. For women who cannot take or tolerate estrogen, it recommends certain antidepressants as second-line options, followed by medications such as gabapentin and newer nonhormonal drugs.
At the same time, the American College of Obstetricians and Gynecologists (ACOG) broadened its existing recommendations in mid-October, adding more detail on hormone therapy for vasomotor-related sleep disturbances and on how to time starting treatment to maximize benefits and minimize risks.
How the ground moved
In November 2025, the FDA removed "black box" warnings from hormone therapy products, after experts concluded the risks had been overstated — and more women have explored treatment since. With its new guidance, the ACP joins ACOG, the Endocrine Society, the American Association of Clinical Endocrinologists and the American Society for Reproductive Medicine in endorsing hormone therapy as the most effective treatment for moderate to severe hot flashes and night sweats.
The honesty beat
Timing is the central caveat. Experts generally advise starting treatment before age 60 or within 10 years of menopause, when the benefit–risk balance is typically more favourable for healthy women. Starting later may increase risks, including heart attack, stroke and dementia. The guidance is an endorsement of a treatment for specific symptoms — not a blanket recommendation for every woman, and Harvard Health's own closing advice is that women considering it discuss their medical history, individual risk factors and preferences with their doctors, because hormone therapy "isn't right for everyone."
Health note: This article summarizes published medical guidance for information only and is not medical advice. Whether hormone therapy is appropriate depends on your individual history and risk factors — talk to your own doctor.
The Twikup Take
For two decades, menopause hormone therapy lived under a cloud of warnings that scared off a generation of women and their doctors. The warnings coming off — and now a first-line endorsement — is what evidence slowly out-arguing fear looks like. The remaining rule is timing: the same treatment is a different bet at 52 than at 68.
Image: Illustrative image.
